

DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. *Info Infeksi Emerging Kementerian Kesehatan RI*. www.infeksiemerging.kemkes.go.id/. Diakses pada 6 September 2020.
2. World Health Organization. *Coronavirus (COVID-19)*.www.covid19.who.int.
Diakses pada 29 September 2021
3. Satuan Tugas Penanganan COVID-19. Peta sebaran COVID-19. www.covid19.go.id/peta-sebaran. Diakses pada 29 September 2021
4. Info Penanggulangan Covid-19 Kota Makassar. Website Resmi Informasi Penanggulangan Covid-19 Pemerintah Kota Makassar. www.infocorona.makassar.go.id. Diakses pada 5 September 2021
5. Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal*. 2020;10(2):102-108.
6. World Health Organization. *Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)* 2020.
7. Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*.2020;180(7):1-10.
8. Köse N, Yıldırım T, Akın F, et al. Prognostic role of NLR, PLR, and LMR in patients with pulmonary embolism. *Bosn J Basic Med Sci*. 2020;20(2):248-253.
9. Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. *Signal Transduct Target Ther*. 2020;5(1):128.
10. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*.

- 2020;71(15):762-768.
11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062
 12. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733.
 13. Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. *Int J Infect Dis*. 2020;96:467-474.
 14. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(4):844-847.
 15. Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J Pathol*. 2020;251(3):228-248.
 16. Bhardwaj A, Sapra L, Saini C, et al. COVID-19: Immunology, Immunopathogenesis and Potential Therapies. *Int Rev Immunol*. 2021;1-36.
 17. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clin Immunol*. 2020;215:108427
 18. Sokolowska M, Lukasik Z, Agache I, et al. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives – a report of the European Academy of Allergy and Clinical Immunology (EAACI). 2020. *Allergy*. Pg:1-73
 19. Zhang B, Zhou X, Zhu C, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome

- for Patients With COVID-19. *Front Mol Biosci.* 2020;7:157
20. Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. *Clin Infect Dis.* 2020;71(16):2027-2034.
21. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the Science. *Immunity.* 2020;52(6):910-941.
22. Felsenstein S, Herbert JA, McNamara PS, et al. COVID-19: Immunology and treatment options. *Clin Immunol.* 2020;215:108448
23. Tay, M.Z., Poh, *et al.* The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 2020;20:363–374
24. de Lucena TMC, da Silva Santos AF, de Lima BR, et al. Mechanism of inflammatory response in associated comorbidities in COVID-19. *Diabetes Metab Syndr.* 2020;14(4):597-600.
25. Lagadinou M, Salomou EE, Zareifopoulos N, et al. Prognosis of COVID-19: Changes in laboratory parameters. *Infez Med.* 2020;28(1):89-95.
26. Lino K, Guimarães GMC, Alves LS, et al. Serum ferritin at admission in hospitalized COVID-19 patients as a predictor of mortality. *Braz J Infect Dis.* 2021;25(2):101569.
27. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol.* 2020;92(7):791-796
28. Cheng K, Wei M, Shen H, et al. Clinical characteristics of 463 patients with common and severe type coronavirus disease (In Chinese) *Shanghai Med J.* 2020:1–15

29. Alkhatip AA, Kamel MG, Hamza MK, et al. The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis. *Expert Review of Molecular Diagnostics*. 2021 May;21(5):505-514
30. Simadibrata DM, Calvin J, Wijaya AD, et al. Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis. *Am J Emerg Med*. 2021;42:60-69
31. Yanga A-P, Liub J, Taoc W, et al. The diagnostic and predictive role of NLR, d- NLR and PLR in COVID-19 patients. *Int Immunopharmacol*. 2020;84:1-7
32. Chan AS, Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. *J Clin Med Res*. 2020 Jul;12(7):448-453.
33. Sarkar S, Kannan S, Khanna P, et al. Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis. *J Med Virol*. 2022;94(1):211-221
34. Man MA, Rajnoveanu RM, Motoc NS, et al. (2021) Neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients. *Plos one*. 2021;16(6): e0252599
35. Aly MM, Meshref TS, Abdelhameid MA, Ahmed SA, Shaltout AS, Abdel-Moniem AE, Hamad DA. Can Hematological Ratios Predict Outcome of COVID-19 Patients? A Multicentric Study. *J Blood Med*. 2021;12:505-515.
36. Prabhu S, Patil N. Study correlating lymphocyte to monocyte ratio and platelet to lymphocyte ratio with the severity in COVID-19 patients: a cross sectional study. *Int J Adv Med*. 2021;8:201-6

37. Chandrashekara S. C-reactive protein: an inflammatory marker with specific role in physiology, pathology, and diagnosis. *IJRCI*. 2014;2:1-23.
38. Baranovskii DS, Klabukov ID, Krasilnikova OA, et al. Prolonged prothrombin time as an early prognostic indicator of severe acute respiratory distress syndrome in patients with COVID-19 related pneumonia. *Curr Med Res Opin*. 2021;37(1):21-25
39. Shen Y, Cheng C, Zheng X, et al. Elevated procalcitonin is positively associated with the severity of covid-19: A meta-analysis based on 10 cohort studies. *Medicina*. 2021;57(6):594
40. Hu R, Han C, Pei S, et al. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents*. 2020 Aug;56(2):106051.
41. Heidari-Beni F, Vahedian-Azimi A, Shojaei S, et al. The Level of Procalcitonin in Severe COVID-19 Patients: A Systematic Review and Meta-Analysis. *Adv Exp Med Biol*. 2021;1321:277-286.
42. Ticinesi A, Nouvenne A, Prati B, et al. The Clinical Significance of Procalcitonin Elevation in Patients over 75 Years Old Admitted for COVID-19 Pneumonia. *Mediators Inflamm*. 2021;2021:5593806.
43. Gómez-Pastora J, Weigand M, Kim J, et al. Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator?. *Clin Chim Acta*. 2020;509:249-251
44. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Lab Anal*. 2020;34(10):1-18.
45. Melo AKG, Milby KM, Caparroz ALMA, et al. Biomarkers of cytokine storm

- as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. *Plos one*. 2021;16(6):e0253894
46. Vajari MK, Shirin M, Pourbagheri-Sigaroodi A, et al. COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. *Cell Biol Int*. 2021;45(9):1832-1850
47. Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. *Clin Chim Acta*. 2020;507:167-173.
48. Zhang A, Leng Y, Zhang Y, et al. Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19. *Int J Infect Dis*. 2020;100:441-448
49. Zou Y, Guo H, Zhang Y, et al. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. *Biosci Trends*. 2020;14(4):285-289
50. Long H, Nie L, Xiang X, et al. D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. *Biomed Res Int*. 2020;2020:1-10
51. Wang L, He WB, Yu XM, et al. Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients. *World J Clin Cases*. 2020;8(19):4370-4379
52. Lin J, Yan H, Chen H, et al. COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis. *J Med Virol*. 2021;93(2):934-944.
53. Devreese KMJ. COVID-19-related laboratory coagulation findings. *Int J Lab Hematol*. 2021;43(1):36-42.

54. Long W, Yang J, Li Z, et al. Abnormal Fibrinogen Level as a Prognostic Indicator in Coronavirus Disease Patients: A Retrospective Cohort Study. *Front Med.* 2021;8:687220
55. Zhou J, Huang L, Chen J, et al. Clinical features predicting mortality risk in older patients with COVID-19. *Curr Med Res Opin.* 2020;36(11):1753-1759
56. Yan X, Li F, Wang X, et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. *J Med Virol.* 2020;92(11):2573-2581
57. Sun S, Cai X, Wang H, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clin Chim Acta.* 2020;507:174-180
58. Qu R, Ling Y, Zhang Y hui zhi, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. *J Med Virol.* 2020;92(9):1533-1541.
59. Liu G, Zhang S, Hu H, et al. The role of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio in the prognosis of type 2 diabetics with COVID-19. *Scott Med J.* 2020;65(4):154-160.
60. Amit M, Sorkin A, Chen J, et al. Clinical course and outcomes of severe covid-19: A national scale study. *J Clin Med.* 2020;9(7):1-12.
61. Bertsimas D, Lukin G, Mingardi L, et al. COVID-19 mortality risk assessment: An international multi-center study. *PLoS One.* 2020;15(12):1-13.
62. Zhang X Bin, Hu L, Ming Q, et al. Risk factors for mortality of coronavirus disease-2019 (COVID-19) patients in two centers of Hubei province, China: A retrospective analysis. *PLoS One.* 2021;16(1):1-15

63. Qiu P, Zhou Y, Wang F, et al. Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis. *Aging Clin Exp Res.* 2020;32(9):1869- 1878.
64. Huang Y, Lyu X, Li D, Wang L, Wang Y, et al. A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19. *PLOS ONE.* 2020;15(11):e0242045.
- 65.1 Long H, Nie L, Xiang X, et al. D Dimer and Prothrombin Time are the significant Indicators of severe COVID-19 and Poor prognosis. *Biomed Research International.* 2020;